|
|
||||||||



* Department of Immunology, Indian Institute of Chemical Biology; and
National Institute of Cholera and Enteric Diseases, Scheme XM, Beliaghata, Kolkata, India
Leishmania donovani-infected splenic macrophages and P388D1 (P388D1(I)) failed to activate T cells in response to low dose of exogenous peptide. The membrane fluidity of P388D1(I) was greater than that of the normal counterpart P388D1(N), but could be reduced either by exposing the cell below phase transition point or by loading cholesterol into membrane (L-P388D1(I)), and this was associated with enhanced Ag-presenting ability of P388D1(I). Presentation of endogenous leishmanial Ag, kinetoplastid membrane protein-11, was also defective, but could be corrected by loading cholesterol into membrane. Because membrane rafts are important for Ag presentation at a low peptide dose, raft architecture of P388D1(I) was studied using raft (CD48 and cholera toxin-B) and non-raft (CD71) markers in terms of their colocalization with I-Ad. Binding of anti-CD48 mAb and cholera toxin B subunit decreased significantly in P388D1(I), and consequently, colocalization with I-Ad was not seen, but this could be restored in L-P388D1(I). Conversely, colocalization between I-Ad and CD71 remained unaffected regardless of the presence or the absence of intracellular parasites. P388D1(N) and L-P388D1(I), but not P388D1(I), formed peptide-dependent synapse with T cells quite efficiently and this was found to be corroborated with both intracellular Ca2+ mobilization in T cells and IL-2 production. This indicated that intracellular parasites disrupt the membrane rafts, possibly by increasing the membrane fluidity, which could be corrected by making the membrane rigid. This may be a strategy that intracellular L. donovani adopts to evade host immune system.
This article has been cited by other articles:
![]() |
S. Banerjee, J. Ghosh, S. Sen, R. Guha, R. Dhar, M. Ghosh, S. Datta, B. Raychaudhury, K. Naskar, A. K. Haldar, et al. Designing Therapies against Experimental Visceral Leishmaniasis by Modulating the Membrane Fluidity of Antigen-Presenting Cells Infect. Immun., June 1, 2009; 77(6): 2330 - 2342. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mookerjee Basu, A. Mookerjee, R. Banerjee, M. Saha, S. Singh, K. Naskar, G. Tripathy, P. K. Sinha, K. Pandey, S. Sundar, et al. Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1080 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Dey, N. Majumder, S. Bhattacharjee, S. B. Majumdar, R. Banerjee, S. Ganguly, P. Das, and S. Majumdar Leishmania donovani-Induced Ceramide as the Key Mediator of Akt Dephosphorylation in Murine Macrophages: Role of Protein Kinase C{zeta} and Phosphatase Infect. Immun., May 1, 2007; 75(5): 2136 - 2142. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Shaikh and M. Edidin Immunosuppressive effects of polyunsaturated fatty acids on antigen presentation by human leukocyte antigen class I molecules J. Lipid Res., January 1, 2007; 48(1): 127 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Shaikh and M. Edidin Polyunsaturated fatty acids, membrane organization, T cells, and antigen presentation Am. J. Clinical Nutrition, December 1, 2006; 84(6): 1277 - 1289. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Browman, M. E. Resek, L. D. Zajchowski, and S. M. Robbins Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER J. Cell Sci., August 1, 2006; 119(15): 3149 - 3160. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mookerjee Basu, A. Mookerjee, P. Sen, S. Bhaumik, P. Sen, S. Banerjee, K. Naskar, S. K. Choudhuri, B. Saha, S. Raha, et al. Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation in Leishmania donovani-Infected Macrophages. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1788 - 1797. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |